archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Frequently Asked Questions | Agendia
    performed on a fresh biopsy specimen Therefore you should let your doctor know before surgery that you would like a ColoPrint test performed after surgery Your doctor can then order a ColoPrint specimen collection kit and inform the pathologist that small pieces of your tumor will be used for the test The specimen collection kit contains all material and instructions necessary for your doctor to take a sample and order the ColoPrint test for you Agendia operates CAP CLIA licensed and compliant FDA registered compliant laboratories in Amsterdam and Irvine California Can ColoPrint help determine what treatment I should get ColoPrint provides information about the specific genomic profile of your tumor and indicates if you have a Low or High Risk that the tumor might come back These results can provide valuable information to you and your physician to make a more informed individualized treatment decision How long does it take to get the results of ColoPrint The ordering physician typically receives the result report about 10 days after Agendia receives the specimen The results are typically discussed during an office visit with your doctor Is the ColoPrint colon cancer test covered by insurance Our mission is to ensure all cancer patients have access to important and clinically relevant molecular diagnostic testing empowering patients and physicians to make the most informed treatment decisions Agendia understands that costs associated with a patient s diagnosis treatment and management of colon cancer can potentially pose a financial hardship which may influence a patient s decision in selecting diagnostic and treatment options Please contact a Patient Advocate for information about your specific coverage They can be reached at 888 363 7868 or email at billing agendia com Agendia is a compassionate company offering a wide range of financial assistance programs based on individual financial

    Original URL path: http://www.agendia.com/patient/colon-cancer-patients/faqs/ (2016-05-01)
    Open archived version from archive


  • Insurance Coverage | Agendia
    HAVE TO PAY FOR MY TEST S A Like each patient every case is unique and the average out of pocket amount varies based on insurance benefits what portion of your deductible has been met and your co pay amounts If you have active insurance coverage at the time of testing Agendia can provide you with an estimate of your financial responsibility based on your specific benefit levels Please call 888 363 7868 and one of our Patient Advocate Representatives will gladly assist you Q WHAT ARE MY PAYMENT OPTIONS IF I HAVE A BALANCE DUE A If payment is required after your insurance company has determined their coverage Agendia will work on your behalf to ensure that the insurance company has processed the claim at the highest benefit level to minimize any out of pocket expense After a full review an invoice will be issued for any difference in coverage If you are interested in arranging an interest free payment plan please contact us and one of our Patient Advocates can assist you with this Q WHAT IF I GET A BILL FROM AGENDIA FOR MORE THAN I EXPECTED A Please contact us and one of our Patient Advocates will work to resolve the discrepancy in an acceptable and timely manner They can be reached at 888 363 7868 Q MY INSURANCE COMPANY SENT ME SOMETHING THAT LOOKS LIKE A BILL FOR THIS TEST SHOULD I PAY IT A Your insurance company may send you one or more Explanation of Benefits EOB statements related to our test s This is not a bill from Agendia Agendia can submit an appeal s on your behalf during the claim review process and each appeal submitted will generate an EOB from your insurance company You do not have any financial obligation for

    Original URL path: http://www.agendia.com/patient/colon-cancer-patients/insurance-coverage/ (2016-05-01)
    Open archived version from archive

  • Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer | Agendia
    Spain January 8 2012 Background Between 25 and 35 of stage II colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy ColoPrint is a gene expression classifier that can predict disease relapse in patients with early stage colorectal cancer Salazar et al JCO 2011 Methods ColoPrint was developed using gene expression data from whole genome microarrays and was validated in in silico datasets and independent patient cohorts from 5 European hospitals Fresh frozen tissues clinical parameters MSI status and follow up data for patients were available Samples were hybridized to Agilent microarrays and the ColoPrint index was determined Uni and multivariate analysis was performed on the pooled stage II patient set n 320 who had a median follow up of 70 months Reproducibility and precision studies were performed using clinical and control samples specific for each outcome level high risk low risk Experiments were performed on 20 days with 2 runs per day by multiple technicians reflecting daily diagnostic conditions Results Performance of the prognostic classifier was confirmed in reproducibility and stability assays and stringent quality controls were established In the clinical validation ColoPrint classified two third of patients 209 320 as low risk The 3 year relapse free survival was 94 for low risk patients and 79 for high risk patients with a HR of 2 74 95 CI 1 54 4 88 p 0 006 MSI status and the number of assessed lymph nodes were the only significant clinical parameters in the univariate analysis Using parameters from the ASCO recommendation T4 perforation less than 12 LN assessed and or high grade for the identification of high risk patients was not significant HR 1 43 95 CI 0 81 2 55 p 0 22 and no clinical parameter added power to the

    Original URL path: http://www.agendia.com/clinical-and-technical-validation-of-a-genomic-classifier-coloprint-for-predicting-outcome-of-patients-with-stage-ii-colon-cancer/ (2016-05-01)
    Open archived version from archive

  • Mark R. Straley | Agendia
    Search for Search More Mark R Straley Chief Executive Officer CEO Mr Mark R Straley joined Agendia Inc in August 2015 as the company s CEO bringing more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services Most recently he served as President Anatomical Pathology of Thermo Fisher Scientific of Waltham Massachusetts Prior to this position he was President and CEO of Metamark Genetics of Cambridge Massachusetts a biotech company focusing on the development of prognostic and predictive diagnostic tests for personalized treatment of cancer patients From 2005 to 2010 Mark held positions at Ortho Clinical Diagnostics a J J company first as Worldwide Vice President of Marketing and then as Worldwide President Prior to his assignment with J J Mark worked for such brand name companies as Bayer Healthcare and Abbott Laboratories where he held positions of increasing responsibility Mark earned a Bachelor of Science degree in Marketing from Miami University We d Love To Hear From You Name Email Questions Comments Concerns Questions Comments Concerns Name This field is for validation purposes and should be left unchanged Resources Online Ordering Publications Studies Physician Education Breast Cancer Colon Cancer Publications Client Login Ordering Patient

    Original URL path: http://www.agendia.com/management/mark-straley/ (2016-05-01)
    Open archived version from archive

  • Kurt Becker | Agendia
    analytics in healthcare banking and aerospace industries His previous public company experience has been at Alphatec Spine Wells Fargo and UTC Aerospace Kurt holds a Master s of Science in Business Administration degree from San Diego State University with a focus on Finance and a Bachelor of Science degree in Finance from the University of Wisconsin Milwaukee We d Love To Hear From You Name Email Questions Comments Concerns Questions

    Original URL path: http://www.agendia.com/management/kurt-becker/ (2016-05-01)
    Open archived version from archive

  • Prof. Laura van ‘t Veer Ph.D. | Agendia
    record in molecular oncology research which includes more than 230 scientific publications and prestigious awards for her contributions to breast cancer care Dr van t Veer is best known for work stemming from a discovery she and her team made at the Netherlands Cancer Institute NKI They established that a specific DNA signature made up of 70 genes distinguished whether breast cancer tumors had a low or high risk of recurrence After patenting their innovation she and research partner René Bernards founded Agendia and launched the MammaPrint test In 2010 Dr van t Veer was appointed Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco She is also the former head of the NKI s DNA diagnostic laboratory She was awarded a 2014 European Union Prize for Women Innovators that acknowledges the ways MammaPrint has helped transform breast cancer care For video click here In 2015 the European Patent Office EPO recognized MammaPrint s impact on breast cancer diagnostics by honouring Dr van t Veer with a European Inventor Award To see video from the EPO about Dr van t Veer s work click here Laura van t Veer Netherlands winner of the

    Original URL path: http://www.agendia.com/management/prof-dr-laura-van-t-veer/ (2016-05-01)
    Open archived version from archive

  • Prof. Dr. René Bernards | Agendia
    30 year track record in oncology research with more than 150 published papers in peer reviewed journals He is the Head of Division of Molecular Carcinogenesis of the Netherlands Cancer Institute professor of Molecular Carcinogenesis at Utrecht University and member of the Royal Netherlands Academy of Arts and Sciences KNAW In addition René is a member of the Scientific Advisory Board of Gilde Healthcare fund We d Love To Hear

    Original URL path: http://www.agendia.com/management/prof-dr-rene-bernards/ (2016-05-01)
    Open archived version from archive

  • Guido Brink | Agendia
    over 20 years of experience in the oncology field and an extensive background in quality assurance systems in the field of molecular diagnostics Prior to joining the Company Guido spent 12 years at the Netherlands Cancer Institute NKI where he supervised the development of biotechnology quality control systems as member of Laura van t Veer s research team co founder of Agendia We d Love To Hear From You Name

    Original URL path: http://www.agendia.com/management/guido-brink/ (2016-05-01)
    Open archived version from archive



  •